SAR 264565

Drug Profile

SAR 264565

Alternative Names: SAR264565

Latest Information Update: 02 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Sanofi Aventis Deutschland GmbH
  • Class Antiplatelets; Fab fragments; Glycoproteins
  • Mechanism of Action Platelet membrane glycoprotein VI inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Thrombosis

Most Recent Events

  • 18 May 2017 Preclinical trials in Thrombosis in Germany (parenteral)
  • 18 May 2017 Pharmacodynamics data from preclinical development in Thrombosis released by Sanofi-Aventis Deutschland GmbH
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top